Close

Avadel Pharma (AVDL) Announces the FDA Review of NDA for FT218 for Patients with Narcolepsy is Still Ongoing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. SPOT
5. V
6. MSCI
7. STX
8. MAT
9. TMO
10. KMB


Go back to Avadel Pharma (AVDL) Announces the FDA Review of NDA for FT218 for Patients with Narcolepsy is Still Ongoing
(NASDAQ: AVDL) Delayed: 18.09 --0 (-0%)
Previous Close $18.09    52 Week High $ 
Open $18.09    52 Week Low $ 
Day High $18.09    P/E N/A 
Day Low $18.09    EPS $ 
Volume 2